JO
SCPH

John Overdeck’s scPharmaceuticals SCPH Stock Holding History

John Overdeck’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,700
Closed -$79.6K – 3343
2023
Q4 		$79.6K Sell
12,700
-19,300
-60% -$111K ﹤0.01% 2962
2023
Q3 		$228K Sell
32,000
-19,000
-37% -$150K ﹤0.01% 2595
2023
Q2 		$520K Sell
51,000
-198,067
-80% -$2.07M ﹤0.01% 2314
2023
Q1 		$2.26M Buy
249,067
+60,112
+32% +$440K 0.01% 1307
2022
Q4 		$1.35M Buy
+188,955
New +$1.15M ﹤0.01% 1544
2020
Q4 		– Sell
-26,369
Closed -$196K – 3707
2020
Q3 		$196K Buy
+26,369
New +$206K ﹤0.01% 2828

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

John Overdeck's SCPH Position: Q1 2024 in Review

John Overdeck sold out of scPharmaceuticals (SCPH) in Q1 2024, closing a stake of 12,700 shares — an estimated $79.6K sold.

John Overdeck first reported a position in SCPH in Q3 2020 and held it in 6 quarters. The position peaked at $2.26M in Q1 2023. 76 funds tracked by Wall St. Rank hold SCPH as of Q1 2024.

  • John Overdeck reported no remaining scPharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • John Overdeck sold 12,700 scPharmaceuticals shares in Q1 2024, an estimated $79.6K.
  • John Overdeck first reported a position in scPharmaceuticals in Q3 2020 and held it in 6 quarters.
  • John Overdeck's scPharmaceuticals position peaked at $2.26M in Q1 2023.
  • 76 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2024.

Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.